Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583171 | 0.87 | MEN1 (0.66) | MEN1KMT2ACYP2D6HPGDNPC1 | |
| SCHEMBL4240412 | 0.87 | MEN1 (0.61) | MEN1KMT2ACYP2D6HSD11B1MGLL | |
| Hydrochloric Acid SCHEMBL21384816 | 0.86 | MEN1 (0.64) | MEN1KMT2ACYP2D6HSD11B1MGLL | |
| SCHEMBL16432191 | 0.86 | MEN1 (0.64) | MEN1KMT2ACYP2D6HSD11B1MGLL | |
| Hydrochloric Acid SCHEMBL11616870 | 0.86 | MEN1 (0.69) | MEN1KMT2ACYP2D6HPGDNPC1 | |
| Hydrochloric Acid SCHEMBL16432405 | 0.84 | MEN1 (0.67) | MEN1KMT2ACYP2D6HSD11B1MGLL | |
| SCHEMBL19220947 | 0.82 | MEN1 (0.59) | MEN1KMT2ACYP2D6HPGDNPC1 | |
| Tert-Butyl Formate SCHEMBL27968807 | 0.81 | MEN1 (0.51) | MEN1KMT2ACYP2D6HSD11B1MGLL | |
| SCHEMBL1582773 | 0.78 | KMT2A (0.96) | MEN1KMT2ACYP2D6HSD11B1MGLL | |
| SCHEMBL228259 | 0.78 | MEN1 (0.67) | MEN1KMT2ACYP2D6HSD11B1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | TNKS, TANK, TBKBP1 | MEN1 4039/4885KMT2A 1418/4885CYP2D6 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.